Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Acquisitions (2017 - 2018)

Ptc Therapeutics has reported Acquisitions over the past 2 years, most recently at $48.9 million for Q3 2018.

  • Quarterly results put Acquisitions at $48.9 million for Q3 2018, up 163.97% from a year ago — trailing twelve months through Dec 2019 was $48.9 million (up 277.58% YoY), and the annual figure for FY2018 was $48.9 million, changed.
  • Acquisitions for Q3 2018 was $48.9 million at Ptc Therapeutics, up from -$76.4 million in the prior quarter.
  • Over the last five years, Acquisitions for PTCT hit a ceiling of $48.9 million in Q3 2018 and a floor of -$76.4 million in Q3 2017.